Sayna Norouzi, MD

Huge thank you to our incredible faculty, attendees, sponsors, and GlomCon instructors for making #GlomConHawaii conference a success! 🌟
We deeply appreciate and value your partnership.
Hope to see you all next year, in Maui August 3-7 ⭐️

Mahalo!! 🌺
@glomcon.org

Huge thank you to our incredible faculty, attendees, sponsors, and GlomCon instructors for making #GlomConHawaii conference a success! 🌟
We deeply appreciate and value your partnership.
Hope to see you all next year, in Maui August 3-7 ⭐️

Mahalo!! 🌺

What a fantastic evening at the #GlomConHawaii reception! Thank you to everyone who joined us🥰
It’s a privilege to be part of such an exceptional community. The future of nephrology is bright. @glomcon.org

Excellent thread below

I will also plug this talk by Paola Romagnani on podocytopathies

youtu.be/bRMeqaGgA9I?...

#GlomCon #NephGR

Home | GlomCon Hawaii GlomCon Hawaii is an annual in-person and hybrid conference dedicated to advancing education, research, and collaboration in nephrology. As part of GlomCon Foundation's initiative, the conference brin...

Register here 👉 glomconhawaii.org

#GlomConHawaii2025
#GlomConHawaii
#GlomCon

This year’s in-person gathering promises to strengthen connections, spark deeper collaboration, and elevate the learning experience in beautiful Hawaii.

Can't join us in person? We plan to live-stream the main sessions; see you on the virtual side.

#GlomConHawaii
#GlomCon

Clinical Endpoints for Glomerular Diseases from
@hjanders.bsky.social
#GlomConHawaii 🌊 #Nephpearls #NephSky

IgA Nephropathy: An Overview of the Clinical Trials IgA nephropathy (IgAN) is characterized by the deposition of poorly-O-galactosylated IgA1 (also referred to as galactose-deficient IgA1 or gd-IgA1) containing immune complexes in the glomerular mesang...

IgA Nephropathy #IgAN: An Overview of the Clinical Trials ca. 2025 from @saynanorouzi.bsky.social
#Nephpearls #NephSky

www.kidneymedicinejournal.org/article/S259...

Thank you 🙌🏻

Congrats @sophia-kidney.bsky.social @saynanorouzi.bsky.social @kashvilunawat.bsky.social

And all the other awardees of the @asnkidney.bsky.social NephCure grants!

www.kidneycure.org/pages/qa.aspx

Thank you!! Always a pleasure to collaborate with you.

Cardiovascular Events in Lupus Nephritis: A Systematic Review and Meta-Analysis - PubMed CVE occurrence among individuals with LN is significant, and this disease entity increases CVE risk, highlighting the importance of implementing early therapeutic interventions to prevent poor outcome...

It’s not just the immune mediated and infections - we need to pay attention to cardiovascular disease in SLE

pubmed.ncbi.nlm.nih.gov/40539000/

Nice job synthesizing the data @saynanorouzi.bsky.social and team!

#NephSky #lupuschat

#GlomConHawaii 2025 🌴🌊 session:
Post-market Evaluations, Registries, and RWE Studies

Register here 👉 glomconhawaii.org

#GlomConHawaii2025
#GlomConHawaii
#GlomCon

Thank you🥰

@saynanorouzi.bsky.social rocks in Vienna #ERA25! @glomcon.org

🚨 Exciting News! 🚨
The GlomCon Foundation, American Kidney Fund, and
IgA Nephropathy Foundation have joined forces to develop the consensus framework for establishing Centers of Excellence in Glomerular Disease Care!

🔗 Learn more: www.glomcon.org/news-release...

Applications are now open for the Polycystic Kidney Disease Medical Directorship Program (PKD-MDP)! 🤩

🔗 Apply here: www.glomcon.org/pkdmd-program
📅 Deadline to apply is July 15, 2025

What’s New and What’s Next in Glomerular Disease Care, with Sayna Norouzi, MD Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

Q1 was full of important advances in #nephrology, especially in glomerular diseases. Hear from @SaynaNorouzi @LLUHealth @GlomCon as she reflects on some of these developments and looks ahead to what might be in store for the rest of 2025:

www.hcplive.com/view...

Venous thromboembolism prevention for nephrotic syndrome: The role of aspirin, vitamin K antagonists and direct oral anticoagulants Nephrotic syndrome (NS) carries a significantly elevated risk of venous thromboembolic events (VTE), contributing to morbidity and mortality. Current guidelines for VTE prophylaxis in NS are based on ...

Are you effectively preventing VTE in your patients with nephrotic syndrome?

Check out our paper below on KI reports about this important topic. It's a fantastic collaboration with some truly brilliant minds! #NephSky @glomcon.org

www.kireports.org/article/S246...

GlomCon is thrilled to introduce a new leadership training opportunity 🤩

The Polycystic Kidney Disease Medical Directorship Program (PKD-MDP) is a year-long, interactive program aiming to deepen participants' expertise in PKD diagnosis and management.

Applications open May 1.

Smoking-modified HTN-associated nodular glomerulosclerosis (SHaNGS), a form of hypertensive glomerulosclerosis in the context of alteration by smoking products.

pmc.ncbi.nlm.nih.gov/articles/PMC11…

Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants ca. 2025 from @kireports.bsky.social @saynanorouzi.bsky.social @kdjhaveri.bsky.social
#Nephpearls #NephSky

👉 www.kireports.org/article/S246...

In August 2024, GlomCon launched its 1st international hybrid conference on GN in Maui.

Diverse group of expert faculty of 52 members, achieving an intentional and balanced gender representation of 50% male and 50% female. The event reached a total of 619 registrations.

karger.com/gdz/article/5/…

IgG4-Related Kidney Disease - PubMed IgG4-Related Kidney Disease

The FDA approved inebilizumab-cdon (UPLIZNA; @Amgen as the first and only treatment for adult patients diagnosed with immunoglobulin G4-related disease (IgG4-RD). #RareDiseases
pubmed.ncbi.nlm.nih.gov/39969992/

Thank you 😃

Thank you, @khon2news.bsky.social News for inviting us this morning to discuss Rare Kidney Disease and the @nkf-professionals.bsky.social (Hawaii). ⭐️

Join us for the NKF Hawaii Kidney walk on Saturday🤍#PatientAdvocacy #RareKidneyDiseases

kidneywalk.org/hawaii

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀! GlomCon has convened an international expert panel to develop criteria for Centers of Excellence—and we’ll share the findings at #GlomConHawaii2025.

Stay tuned for more updates on our new clinics and workshop!

#GlomCon

Your generosity during #NationalKidneyMonth will be matched dollar-for-dollar, up to $50,000. That means your gift will have twice the power to change lives and bring hope to those affected by kidney disease. Make an impacthttps://buff.ly/41htQVh

T3d: Here are the trials with cell B blockers (yeah, induction, refractory LN, or whatever). Any notable differences in their design? #nephjc